<DOC>
	<DOC>NCT00895037</DOC>
	<brief_summary>The purpose of this observational study is to describe the incidence of adverse events among patients treated with Refacto AF in usual health care settings in Germany and Austria.</brief_summary>
	<brief_title>Study Evaluating Pharmacovigilance Of Refacto AF</brief_title>
	<detailed_description>Non-interventional study: subjects to be selected according to the usual clinical practice of their physician</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Patients with hemophilia A of any severity already receiving or starting treatment with ReFacto AF. Patients with Hemophilia A treated with a product other than Refacto AF.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>